Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03598036 · ClinicalTrials.gov registry record · Phase 2
Dose-Exploration Evaluating the Efficacy and Safety of Voclosporin in Subjects With Focal Segmental Glomerulosclerosis
A Phase 2 study, sponsored by Aurinia Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT03598036 is a Phase 2 study that was terminated before completion, run by Aurinia Pharmaceuticals. The registered enrollment target is 5 participants.
The verdict
NCT03598036, a Phase 2 study, was terminated before completion, sponsored by Aurinia Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
Evaluating the Efficacy and Safety of Voclosporin in Achieving Complete or Partial Remission of Proteinuria in Subjects with Focal Segmental Glomerulosclerosis
Interventions
- DRUG Voclosporin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2018-06-21 |
| Est. Completion | 2020-05-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03598036
The ClinicalTrials.gov registry entry for NCT03598036 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aurinia Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Voclosporin is the first listed.
NCT03598036 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03598036 about?
NCT03598036 is a clinical study titled "Dose-Exploration Evaluating the Efficacy and Safety of Voclosporin in Subjects With Focal Segmental Glomerulosclerosis". Evaluating the Efficacy and Safety of Voclosporin in Achieving Complete or Partial Remission of Proteinuria in Subjects with Focal Segmental Glomerulosclerosis
What is the current status of trial NCT03598036?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2018-06-21. Estimated completion is 2020-05-19.
What interventions are being tested in trial NCT03598036?
The interventions under investigation include: Voclosporin (DRUG).
Who is sponsoring clinical trial NCT03598036?
This trial is sponsored by Aurinia Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.